Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atlantic Sapphire (AASZF)
OTHER OTC:AASZF
Holding AASZF?
Track your performance easily
AASZF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range<$0.01 - $0.28
Previous Close$0.01
Volume344.61K
Average Volume (3M)467.71K
Market Cap
$56.35M
Enterprise Value$79.73M
Total Cash (Recent Filing)$23.61M
Total Debt (Recent Filing)$46.99M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Apr 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding153,266,409
10 Day Avg. Volume189,168
30 Day Avg. Volume467,715
Standard Deviation0.26
R-Squared0.17
Alpha-0.12
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)1.28
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.56
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Atlantic Sapphire News
PremiumCompany Announcements
Atlantic Sapphire Restructures Share Option Scheme
PremiumCompany Announcements
Atlantic Sapphire Expands Capital for Growth
PremiumCompany Announcements
Atlantic Sapphire Expands Share Capital for Growth
PremiumCompany Announcements
Atlantic Sapphire Launches Major Rights Issue for ExpansionPremiumCompany Announcements
Atlantic Sapphire Expands with Major Rights Issue
PremiumCompany Announcements
Nokomis Capital Ups Stake in Atlantic SapphirePremiumCompany Announcements
Condire Management Amplifies Stake in Atlantic Sapphire
PremiumCompany Announcements
Atlantic Sapphire Expands Share Capital and WarrantsOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
― Other Institutional Investors
99.99% Public Companies and
Individual Investors
AASZF FAQ
What was Atlantic Sapphire’s price range in the past 12 months?
Atlantic Sapphire lowest stock price was <$0.01 and its highest was $0.28 in the past 12 months.
What is Atlantic Sapphire’s market cap?
Currently, no data Available
When is Atlantic Sapphire’s upcoming earnings report date?
Atlantic Sapphire’s upcoming earnings report date is Apr 11, 2025 which is in 110 days.
How were Atlantic Sapphire’s earnings last quarter?
Atlantic Sapphire released its earnings results on Aug 20, 2024. The company reported -$0.069 earnings per share for the quarter, missing the consensus estimate of -$0.025 by -$0.044.
Is Atlantic Sapphire overvalued?
According to Wall Street analysts Atlantic Sapphire’s price is currently Overvalued.
Does Atlantic Sapphire pay dividends?
Atlantic Sapphire does not currently pay dividends.
What is Atlantic Sapphire’s EPS estimate?
Atlantic Sapphire’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atlantic Sapphire have?
Atlantic Sapphire has 7,170,808,600 shares outstanding.
What happened to Atlantic Sapphire’s price movement after its last earnings report?
Atlantic Sapphire reported an EPS of -$0.069 in its last earnings report, missing expectations of -$0.025. Following the earnings report the stock price went down -28.571%.
Which hedge fund is a major shareholder of Atlantic Sapphire?
Currently, no hedge funds are holding shares in AASZF
---
Atlantic Sapphire Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
-95.68%
12-Months-Change
Fundamentals
Return on Equity
-48.27%
Trailing 12-Months
Asset Growth
-10.18%
Trailing 12-Months
Company Description
Atlantic Sapphire
Atlantic Sapphire AS is engaged in farming Atlantic salmon.
---
AASZF Company Deck
---
AASZF Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company in transition, with significant improvements in farm performance and stability. Financially, they maintain a strong liquidity position, and their market positioning is promising. However, challenges remain, including higher-than-expected maturation levels affecting biological performance and pricing strategies impacting revenue. While there are headwinds, the outlook is cautiously optimistic with the Phase 2 expansion underway.Read More>---
Technical Analysis
---